Palabras clave
Ciclosporina A
Tratamiento biológico
Dupilumab
Omalizumab
Posición de consenso
Resumen
Antecedentes: Los abordajes diagnósticos y las estrategias terapéuticas de la dermatitis atópica generalmente son inconsistentes entre los médicos y entre las instituciones de salud.
Objetivo: Consensar las opiniones de expertos para reducir las variaciones en la práctica respecto al diagnóstico y tratamiento de pacientes ≥ 12 años con dermatitis atópica para mejorar su cuidado.
Métodos: Búsqueda sistemática de la literatura en PubMed y GREAT. Con apoyo metodológico y utilizando el método Delphi se desarrolló un consenso formal entre 16 expertos en dermatología y alergología, basándose en la evidencia actual y su aplicabilidad en el contexto mexicano. A parte de una comunicación electrónica intensa, se discutieron los puntos en desacuerdo en dos reuniones presenciales.
Resultados: Los expertos clínicos alcanzaron consenso en 46 declaraciones relacionadas con la definición, clasificación, estrategias de diagnóstico y tratamiento de la dermatitis atópica. Para el diagnóstico sugerimos se usan los criterios de Williams y el SCORAD (por parte del médico) y POEM (por parte del paciente) para definir la gravedad. Aunado a cuidados generales y educación terapéutica, sugerimos cuatro pasos para tratamiento, según gravedad: 1. Manejo tópico con antiinflamatorio (y sistémico: antihistamínico/antileucotrieno —evidencia reducida—) 2. Fototerapia, 3. Ciclosporina A y 4. Dupilumab, con la posibilidad de manejarlo antes si se necesita efecto rápido. En la dermatitis atópica extrínseca sugerimos agregar inmunoterapia con alérgenos o una dieta de eliminación si existe una alergia IgE-mediada, inhalatoria o alimentaria, respectivamente.
Conclusión: El panel de expertos realizó consenso en aspectos relevantes de la dermatitis atópica con enfoque en la adaptación transcultural de evidencia reciente
Referencias
Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods and their use in clinical guideline development. Health Technol Assess. 1998;2(3):1-88. DOI: 10.3310/hta2030
Bieber T. How to define atopic dermatitis? Dermatol Clin. 2017;35(3):275-281. DOI: 10.1016/j.det.2017.02.001
Kantor R, Thyssen JP, Paller AS, Silverberg JI. Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis and recommendation for uniform use of “atopic dermatitis”. Allergy. 2016;71(10):1480-1485. DOI: 10.1111/all.12982
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-836. DOI: 10.1016/j.jaci.2003.12.591
Kim HS, Kim JH, Seo YM, Chun YH, Yoon JS, Kim HH, et al. Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(5):441-445. DOI: 10.1016/j.anai.2017.06.022
Guía de práctica clínica. Tratamiento de la dermatitis atópica. Evidencias y recomendaciones. México: Centro Nacional de Excelencia Tecnológica en Salud; 2014.
Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-765. DOI: 10.1111/j.1365-2133.2007.08412.x
Ortiz-De-Frutos FJ, Guerra-Tapia A, Gómez-De la Cámara A, De la Cruz-Bertolo J, Alvarez-Fernández JG, De la Mano-Orejón D. Validation of the Spanish version of the diagnostic questionnaire of the Working Group on Atopic Dermatitis of the United Kingdom. Rev Clin Esp. 1998;198(7):424-428.
Diagnóstico y manejo de la dermatitis atópica desde el nacimiento hasta los 16 años de edad en el primer nivel de atención. México: Centro Nacional de Excelencia Tecnológica en Salud; 2009.
Barbarot S, Aubert H, Bernier C, Stalder J. Dermatitis atópica. EMC. 2016;50(4):1-22. DOI: 10.1016/S1761-2896(16)80892-4
Liu P, Zhao Y, Mu ZL, Lu QJ, Zhang L, Yao X, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis. Chin Med J (Engl). 2016;129(7):757-762. DOI: 10.4103/0366-6999.178960
Hanifin JM. Adult-onset atopic dermatitis: fact or fancy? Dermatol Clin. 2017;35(3):299-302. DOI: 10.1016/j.det.2017.02.009
Silvestre-Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78-88. DOI: 10.18176/jiaci.0138
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769-779. DOI: 10.1016/j.jaci.2014.08.008
Thijs JL, Strickland I, Bruijnzeel-Koomen C, Nierkens S, Giovannone B, et al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. J Allergy Clin Immunol. 2017;140(3):730-737. DOI: 10.1016/j.jaci.2017.03.023
Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, De Guzman-Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361-370. DOI: 10.1016/j.jaci.2013.04.046
Sánchez J, Páez B, Macías A, Olmos C, De Falco A. Atopic dermatitis guideline. Position paper from the Latin American Society of Allergy, Asthma and Immunology. Rev Alerg Mex. 2014;61(3):178-211.
Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729-747. DOI: 10.1111/jdv.13599
Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018;19(3):293-302. DOI: 10.1007/s40257-017-0340-7
Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, Von-Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69-79. DOI: 10.1111/bjd.14773
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513-1519.
Andearsen YMF, Egeberg A, Skov L, Thyssen JP. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep. 2017;6(1):35-41. DOI: 10.1007/s13671-017-0168-7
Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243-252. DOI: 10.1016/j.alit.2016.04.011
Pols DH, Wartna JB, Moed H, Van-Alphen EI, Bohnen AM, Bindels PJ. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2):143-150. DOI: 10.3109/02813432.2016.1160629
WAO White Book on Allergy. USA: World Allergy Organization; 2013.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. DOI: 10.1111/j.1600-0447.1983.tb09716.x
Tsintsadze N, Beridze L, Tsintsadze N, Krichun Y, Tsivadze N, Tsintsadze M. Psychosomatic aspects in patients with dermatologic diseases. Georgian Med News. 2015(243):70-75.
Lim VZ, Ho RC, Tee SI, Ho MS, Pan JY, Lim YL, et al. Anxiety and depression in patients with atopic dermatitis in a Southeast Asian tertiary dermatological centre. Ann Acad Med Singapore. 2016;45(10):451-455.
Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428-433. DOI: 10.1016/j.jaci.2012.10.041
Arkwright PD, Motalari C, Subramanian H, Spergel J, Schneider LC, Wollenberg A, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(2):142-151.
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176-1193. DOI: 10.1111/j.1468-3083.2012.04636.x
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. DOI: 10.1016/j.jaad.2014.03.023
Eichenfield LF, Call RS, Forsha DW, Fowler J, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2 % in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641-649. DOI: 10.1016/j.jaad.2017.06.010
Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2018;178(3):659-662. DOI: 10.1111/bjd.16046
Belloni Fortina A, Neri L. Antibiotic therapy in the management of atopic dermatitis. G Ital Dermatol Venereol. 2015;150(3):321-325.
SanMiguel AJ, Meisel JS, Horwinski J, Zheng Q, Grice EA. Topical antimicrobial treatments can elicit shifts to resident skin bacterial communities and reduce colonization by staphylococcus aureus competitors. Antimicrob Agents Chemother. 2017;61(9). DOI: 10.1128/AAC.00774-17
Devillers AC, Oranje AP. Wet-wrap treatment in children with atopic dermatitis: a practical guideline. Pediatr Dermatol. 2012;29(1):24-27. DOI: 10.1111/j.1525-1470.2011.01691.x
Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218-1233. DOI: 10.1016/j.jaad.2014.08.038
Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110-117. DOI: 1016/j.jaci.2013.02.044
Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728-745. DOI: 10.1111/pai.12807
Tam HH, Calderon MA, Manikam L, Nankervis H, Núñez IG, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. Allergy. 2016;71(9):1345-1356. DOI: 10.1111/all.12932
Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-299. DOI: 10.1016/j.jaci.2012.12.672
Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556-568. DOI: 10.1016/j.jaci.2015.04.047
Giachetti A, Greco M, Scacchi M, Flores R, Castro C. Consenso Nacional de Dermatitis Atópica 2013. Argentina: Sociedad Argentina de Dermatología; 2013.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. DOI: 10.1016/j.jaad.2014.03.030
Ortiz-Salvador JM, Pérez-Ferriols A. Phototherapy in Atopic Dermatitis. Adv Exp Med Biol. 2017;996:279-286.
Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583-593. DOI: 10.1016/j.jaci.2011.05.04Z
Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353-359. DOI: 10.1016/j.jaci.2011.03.024
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-2294. DOI: 10.1111/jdv.13354
Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839-846. DOI: 10.1016/S0140-6736(06)68340-2
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145-165. DOI: 10.1007/s40257-017-0324-7
Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139. DOI: 10.1056/NEJMoa1314768
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871. DOI: 10.1016/j.jaad.2018.01.01.
Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, Sole D. Omalizumab as third-line therapy for urticaria during pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326-327. DOI: 10.18176/jiaci.0179
Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibi S, Schnopp C, et al. Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. J Allergy Clin Immunol. 2017;140(3):845-853.e3. DOI: 10.1016/j.jaci.2017.01.029
Stalder JF, Barbarot S, Wollenberg A, Holm EA, De-Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114-1121. DOI: 10.1111/j.1398-9995.2011.02577.x
Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol. 2018;19(1):15-22. DOI: 10.1007/s40257-017-0299-4.
Bannister MJ, Freeman S. Adult-onset atopic dermatitis. Australas J Dermatol. 2000;41(4):225-228. DOI: 10.1046/j.1440-0960.2000.00442.x
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99-106. DOI: 10.1111/j.1398-9995.2011.02719.x
Barbier N, Paul C, Luger T, Allen R, De-Prost Y, Papp K, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1 % randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96-102. DOI: 10.1111/j.1365-2133.2004.05696.x
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2018 Revista Alergia México